Tysabri and PML: What Ongoing Monitoring Involves

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML) and what monitoring is required. The medical community has long recognized that immunomodulatory therapies require careful oversight to balance benefits and risks. This page reviews what current reports indicate about PML monitoring for Tysabri patients in Texas.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Building on the broader context of health risk communication, this section delves into the specific medical and scientific evidence connecting Tysabri (natalizumab) to PML. Tysabri is a monoclonal antibody used to treat relapsing forms of multiple sclerosis (MS) and Crohn's disease. It works by binding to alpha-4 integrins on immune cells, preventing their migration into the central nervous system. While this reduces inflammation, it also impairs immune surveillance, allowing the John Cunningham (JC) virus to reactivate and cause PML—a severe, often fatal demyelinating disease. The mechanistic pathway is well-documented: Tysabri inhibits immune cell trafficking, reducing the normal immune response that keeps JC virus in check. In seropositive patients, the virus can infect oligodendrocytes, leading to lytic destruction and demyelination. Risk factors include JC virus antibody positivity, prior immunosuppressant use, and therapy duration exceeding 24 months. Clinical presentation involves subacute neurological deficits such as hemiparesis, ataxia, and cognitive decline. Diagnosis relies on MRI and JC virus DNA detection in cerebrospinal fluid. Early discontinuation of Tysabri and plasma exchange may improve outcomes, but neurological damage is often irreversible.

Adequacy of Warnings and Legal Considerations for Affected Patients

The adequacy of warnings regarding Tysabri and PML has been a subject of scrutiny. Tysabri was initially withdrawn in 2005 after PML reports but reintroduced in 2006 under a restricted distribution program called TOUCH. Despite monitoring protocols, questions remain about whether patients and healthcare providers were fully informed of the magnitude of PML risk, especially with long-term therapy and JC virus antibody status. Some patients allege that risks were downplayed or monitoring insufficient. For those who develop PML, legal considerations may arise under product liability and failure to warn theories. Attorneys specializing in pharmaceutical injury evaluate whether the manufacturer provided adequate warnings, whether the drug was defectively designed, or whether post-market surveillance was negligent. In Texas, affected patients may seek compensation for medical expenses, lost wages, pain and suffering, and other damages. Key evidence includes documentation of JC virus antibody status, duration of therapy, and timeline of symptom onset. Expert testimony from neurologists and pharmacologists is often used to establish causation. Evidence of inadequate warnings—such as failure to highlight increasing risk over time or recommend regular JC virus antibody testing—can strengthen a claim.

Risk Context and the Role of Legal Representation

For patients harmed by Tysabri-associated PML, legal representation can help navigate the complexities of pharmaceutical injury claims. The risk of PML is not uniform; it increases with longer treatment duration and in patients with JC virus antibodies. Despite risk mitigation strategies like the TOUCH program, some patients have suffered devastating neurological consequences. An experienced attorney can assess whether the drug manufacturer failed to adequately warn about these risks or whether there were defects in the drug's design or monitoring protocols. In Texas, product liability laws allow for claims based on inadequate warnings, design defects, and negligence. Affected individuals should seek legal counsel to evaluate their case, gather necessary medical records, and pursue compensation for their injuries. The goal is to hold responsible parties accountable and secure resources for ongoing care and support.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Tysabri and Progressive Multifocal Leukoencephalopathy (PML)?

Tysabri (natalizumab) is a monoclonal antibody that treats multiple sclerosis and Crohn's disease by preventing immune cells from entering the central nervous system. This mechanism can allow the JC virus to reactivate, leading to PML, a severe demyelinating disease. Risk factors include JC virus antibody positivity, prior immunosuppressant use, and treatment duration over 24 months.

What legal options are available for individuals who developed PML after taking Tysabri?

Individuals who developed PML after Tysabri use may pursue product liability claims based on inadequate warnings, design defects, or negligence. An attorney can evaluate whether the manufacturer failed to adequately communicate PML risks or implement sufficient monitoring. In Texas, affected patients may seek compensation for medical expenses, lost wages, and pain and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.